• This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118
RESILIENCE helps you survive cancer with a strong heart
Icon-twitter-x Youtube Facebook Linkedin Instagram

Day: 25 September 2026

Cardiac Surveillance for Anthracycline Cardiotoxicity: Clinical Yield in Low-to-Intermediate Risk Patients: MATRIX Study

This article explains the evaluation carried out in the MATRIX study on the clinical value of intensive cardiac surveillance in low- to intermediate-risk lymphoma patients receiving anthracycline-based chemotherapy. Among 44 patients followed for 10 months, no cases of symptomatic heart failure, cardiovascular death, or major cardiovascular events were observed. Although cancer therapy-related cardiac dysfunction (CTRCD) […]

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions